ODTX — Odyssey Therapeutics, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1882782 ·
Last close
$19.37
Market Cap
$931.07M
52W High
$29.05
52W Low
$15.10
ADV30
309,000
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -53,361,000 -53,059,000 438,100,000 80,641,000 62,328,000
Jun 2026 0 — -46,737,000 -52,788,000 483,850,000 82,031,000 62,629,000
Mar 2026 0 — -39,671,000 -38,262,000 229,070,000 35,719,000 752,764,000
Dec 2025 0 — -37,479,000 -33,515,000 269,788,000 41,687,000 758,066,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-142,414,000
Investing CF
$-121,824,000
Financing CF
$295,407,000
CapEx
$-1,066,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.40
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-712,248,000
Inventory
—
Receivables
—
ST Investments
$245,360,000
EBIT TTM
$-178,507,000
Pretax Income TTM
$-178,561,000
Interest Exp TTM
$54,000
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$0
EBITDA
$-167,428,000
Free Cash Flow
$-85,049,128
Enterprise Value
$619,383,424
Total Cash
$326,000,992
Total Debt
$23,478,000
Shares Out
48,067,877
Trailing EPS
$-6.33
Book Value
$7.84
ROE
-85.5%
ROA
-41.7%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 2,976,000 -161,156,000 -148,647,000 269,788,000 758,066,000 -488,278,000 -129,468,000
Dec 2024 4,472,000 -135,223,000 -129,321,000 197,435,000 579,962,000 -382,527,000 -117,471,000
Dec 2023 1,037,000 -133,439,000 -125,938,000 286,521,000 549,229,000 -262,708,000 -112,728,000
Dec 2022 0 -122,776,000 -124,665,000 317,150,000 461,770,000 -144,620,000 -99,842,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$483,850,000
Forward EPS
$-4.36

Peers — same industry

TickerNameMarket CapLastDaily %
IMTX Immatics N.V. $957.50M $6.29 —
PRME Prime Medicine, Inc. $854.20M $3.84 —
BBTX Bambusa Therapeutics, Inc. $832.91M $16.35 —
MGTX MeiraGTx Holdings plc $826.80M $8.46 —
INBX Inhibrx Biosciences, Inc. $1.09B $74.18 —

News headlines (Yahoo Finance, 1h cache)

Odyssey Therapeutics Announces Publication Highlighting Differentiated Therapeutic Potential of TNFR2 Agonism
2026-11-10 13:00 · Yahoo
Odyssey Therapeutics: Q3 Earnings Snapshot
2026-11-04 12:39 · Yahoo
Odyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-04 12:00 · Yahoo
Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts
2026-10-25 16:02 · Yahoo
Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026
2026-10-20 11:00 · Yahoo
Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026
2026-10-12 12:00 · Yahoo
Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026
2026-10-06 12:00 · Yahoo
Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum
2026-09-16 12:00 · Yahoo
Odyssey Therapeutics (ODTX) Banks Two More Years As Trials Multiply
2026-09-14 02:44 · Yahoo
Odyssey Therapeutics to Participate in Upcoming Investor Conferences
2026-08-26 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.